Cyclin-Dependent Kinase 6
"Cyclin-Dependent Kinase 6" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cyclin-dependent kinase 6 associates with CYCLIN D and phosphorylates RETINOBLASTOMA PROTEIN during G1 PHASE of the CELL CYCLE. It helps regulate the transition to S PHASE and its kinase activity is inhibited by CYCLIN-DEPENDENT KINASE INHIBITOR P18.
| Descriptor ID |
D051361
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.646.500.937 D12.644.360.250.515 D12.776.167.200.515 D12.776.476.250.515
|
| Concept/Terms |
Cyclin-Dependent Kinase 6- Cyclin-Dependent Kinase 6
- Cyclin Dependent Kinase 6
- Cell Division Protein Kinase 6
- Cdk6 Protein Kinase
- Protein Kinase, Cdk6
- CDK6 Protein
- PLSTIRE Protein
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase 6".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase 6".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase 6" by people in this website by year, and whether "Cyclin-Dependent Kinase 6" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 2 | 3 |
| 2009 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 3 | 2 | 5 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 3 | 4 | 7 |
| 2018 | 4 | 4 | 8 |
| 2019 | 3 | 2 | 5 |
| 2020 | 2 | 1 | 3 |
| 2021 | 3 | 4 | 7 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 5 | 6 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase 6" by people in Profiles.
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
-
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I). JCO Precis Oncol. 2024 Sep; 8:e2400418.
-
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers. Cancer Res. 2023 10 02; 83(19):3264-3283.
-
Distinct Mechanisms of Resistance to CDK4/6 Inhibitors Require Specific Subsequent Treatment Strategies: One Size Does Not Fit All. Cancer Res. 2023 10 02; 83(19):3165-3167.
-
Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time. Cancer Res. 2023 03 15; 83(6):939-955.
-
Controlling cell proliferation by targeting cyclin-dependent kinase 6 using drug repurposing approach. Adv Protein Chem Struct Biol. 2023; 135:97-124.
-
CDK4/6 inhibitor palbociclib promotes SARS-CoV-2?cell entry by down-regulating SKP2 dependent ACE2 degradation. Antiviral Res. 2023 04; 212:105558.
-
Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Cancer. 2023 04 01; 129(7):1051-1063.
-
Interferon Signaling in Estrogen Receptor-positive Breast Cancer: A Revitalized Topic. Endocrinology. 2022 01 01; 163(1).
-
A proteogenomic portrait of lung squamous cell carcinoma. Cell. 2021 08 05; 184(16):4348-4371.e40.